25 related articles for article (PubMed ID: 8838150)
1. Androgen ablation leads to an upregulation and intranuclear accumulation of deoxyribonuclease I in rat prostate epithelial cells paralleling their apoptotic elimination.
Rauch F; Polzar B; Stephan H; Zanotti S; Paddenberg R; Mannherz HG
J Cell Biol; 1997 May; 137(4):909-23. PubMed ID: 9151693
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.
Varisli L; Tolan V; Cen JH; Vlahopoulos S; Cen O
Oncol Res; 2022; 30(3):137-155. PubMed ID: 37305018
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer.
Mishra S; Deng JJ; Gowda PS; Rao MK; Lin CL; Chen CL; Huang T; Sun LZ
Oncogene; 2014 Jul; 33(31):4097-106. PubMed ID: 24037531
[TBL] [Abstract][Full Text] [Related]
4. Increased CK5/CK8-positive intermediate cells with stromal smooth muscle cell atrophy in the mice lacking prostate epithelial androgen receptor.
Niu Y; Wang J; Shang Z; Huang SP; Shyr CR; Yeh S; Chang C
PLoS One; 2011; 6(7):e20202. PubMed ID: 21754978
[TBL] [Abstract][Full Text] [Related]
5. DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells.
Song K; Wang H; Krebs TL; Wang B; Kelley TJ; Danielpour D
Mol Endocrinol; 2010 Oct; 24(10):2019-29. PubMed ID: 20739403
[TBL] [Abstract][Full Text] [Related]
6. Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II.
Song K; Wang H; Krebs TL; Kim SJ; Danielpour D
Cancer Res; 2008 Oct; 68(19):8173-82. PubMed ID: 18829577
[TBL] [Abstract][Full Text] [Related]
7. TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts.
Salm SN; Burger PE; Coetzee S; Goto K; Moscatelli D; Wilson EL
J Cell Biol; 2005 Jul; 170(1):81-90. PubMed ID: 15983059
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta 2 heterozygous mutant mice exhibit Cowper's gland hyperplasia and cystic dilations of the gland ducts (Cowper's syringoceles).
Dünker N; Aumüller G
J Anat; 2002 Aug; 201(2):173-83. PubMed ID: 12220125
[TBL] [Abstract][Full Text] [Related]
9. Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Wikström P; Bergh A; Damber JE
Urol Res; 1997; 25(2):103-11. PubMed ID: 9144876
[TBL] [Abstract][Full Text] [Related]
10. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens.
Kyprianou N; Isaacs JT
Endocrinology; 1988 Oct; 123(4):2124-31. PubMed ID: 2901342
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta1 and prostate cancer.
Wikström P; Bergh A; Damber JE
Scand J Urol Nephrol; 2000 Apr; 34(2):85-94. PubMed ID: 10903068
[TBL] [Abstract][Full Text] [Related]
12. Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression.
Kim IY; Ahn HJ; Zelner DJ; Park L; Sensibar JA; Lee C
Mol Endocrinol; 1996 Jan; 10(1):107-15. PubMed ID: 8838150
[TBL] [Abstract][Full Text] [Related]
13. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death.
Kyprianou N; Isaacs JT
Mol Endocrinol; 1989 Oct; 3(10):1515-22. PubMed ID: 2608047
[TBL] [Abstract][Full Text] [Related]
14. Developmental and hormonal regulation of transforming growth factor-alpha and epidermal growth factor receptor gene expression in isolated prostatic epithelial and stromal cells.
Itoh N; Patel U; Skinner MK
Endocrinology; 1998 Mar; 139(3):1369-77. PubMed ID: 9492074
[TBL] [Abstract][Full Text] [Related]
15. Regional expression of transforming growth factor-alpha in rat ventral prostate during postnatal development, after androgen ablation, and after androgen replacement.
Banerjee S; Banerjee PP; Zirkin BR; Brown TR
Endocrinology; 1998 Jun; 139(6):3005-13. PubMed ID: 9607812
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
